Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer

Completed · Phase 2

Conditions studied: Colorectal Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Cyclosporine may relieve the diarrhea caused by irinotecan. PURPOSE: Phase II trial to study the effectiveness of irinotecan and cyclosporine in treating patients who have metastatic, advanced, or locally recurrent colorectal cancer that has not responded to fluorouracil.

Key facts

Study ID

NCT00003950

Run by

University of Chicago

People needed

16

Starts

2000-01-01

Expected to finish

2005-01-01

Last updated by the study team

2014-03-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Illinois at Chicago — Chicago, Illinois, United States
• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Louis A. Weiss Memorial Hospital — Chicago, Illinois, United States
• Cancer Care Specialists of Central Illinois, S.C. — Decatur, Illinois, United States
• Evanston Northwestern Health Care — Evanston, Illinois, United States
• Division of Hematology/Oncology — Park Ridge, Illinois, United States
• Oncology/Hematology Associates of Central Illinois, P.C. — Peoria, Illinois, United States
• Central Illinois Hematology Oncology Center — Springfield, Illinois, United States
• Fort Wayne Medical Oncology and Hematology, Inc. — Fort Wayne, Indiana, United States
• Michiana Hematology/Oncology P.C. — South Bend, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.